Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia

A Prospective Study for the Effects of Chronic Use of Doxazosin on Alpha 1-adrenergic Receptors in Men With Benign Prostatic Hyperplasia

In this study, we investigate the changes of the expression of alpha adrenergic receptor in the prostate tissue during 2-yr medication period in the man with benign prostatic hyperplasia. And we also evaluate the efficacy and safety of 24 mo-treatment with doxazosin (4mg, 8mg)

To compare the expression of alpha-1 adrenergic receptors, we will use various methodologies such as

• Real-time RT-PCR
• Radioligand receptor binding
• Western blot
• Immunohistochemistry

Inclusion Criteria:

• 50 yrs or greater
• International prostatic symptom score >= 8
• Maximal flow rate < 15mL/sec
• baseline PSA 2.5-10 ng/mL
• Pathologically proven BPH
• No medication history for BPH
• Able to give fully informed consent

Exclusion Criteria:

• Previous use of alpha-blocker, 5-alpha reductase inhibitor
• Previous surgery for BPH
• Urologic cancer history
• Urethral stricture
• baseline PSA > 10ng/mL
• BP < 90/70 mmHg
• Orthotopic hypotension with syncope
• Serum Cr > 2.0 mg/dl, alanine aminotransferase > 1.5 times of normal limit
• Bacterial prostatitis within 1 year
• Urinary tract infection(UTI) more than 2 times within 1 year
• Active UTI or prostate biopsy within 1 month
• Unable to void
• Ped use because of incontinence
• Hypersensitivity to alpha-blocker that include quinazoline
• Unstable angina, Myocardial infarction, or cerebrovascular accident within 6 months
• Neurogenic bladder dysfunction (ex. multiple sclerosis, Parkinson's disease, Spinal injury etc.)
• Psychiatric problem
• Alcohol abuse or other drug abuse history
• Severe comorbidities unable to perform long-term trial
• seems not to be appropriate to this study because of any other reasons